椎旁神经阻滞预防乳腺癌术后慢性疼痛的荟萃分析
该荟萃分析评估椎旁神经阻滞(PVB)预防乳腺癌术后慢性疼痛(CPSP)的疗效,纳入12项研究。6个月时PVB与对照在CPSP预防上无显著差异(RR 0.82,95%CI 0.62-1.08),但PVB可预防慢性术后神经病理性疼痛(CPSNP)(RR 0.51,95%CI 0.31-0.85)。
要点
- PVB不能显著降低乳腺癌术后6个月CPSP风险(RR 0.82,95%CI 0.62-1.08)。
- PVB可降低6个月CPSNP风险(RR 0.51,95%CI 0.31-0.85),证据质量低。
- 3个月和12个月CPSP风险与对照无显著差异。
核心结论
- PVB未能显著预防乳腺癌术后CPSP,但可能通过影响急性向慢性疼痛转化来预防CPSNP。
研究设计与样本
- 荟萃分析,检索Medline、Embase、CENTRAL等数据库至2020年4月,纳入12项比较PVB与对照的研究。
- 6个月时间点数据来自7项研究(2161例患者),12个月数据来自7项研究(2087例患者)。
主要发现
- 6个月CPSP风险PVB与对照无差异(RR 0.82,95%CI 0.62-1.08),证据质量中等。
- 3个月CPSP风险无差异(RR 0.78,95%CI 0.57-1.06)。
- 12个月CPSP风险无差异(RR 0.45,95%CI 0.14-1.41)。
- 6个月CPSNP风险PVB低于对照(RR 0.51,95%CI 0.31-0.85),证据质量低。
关键数值与推荐
- 主要结局为6个月CPSP,次要结局包括3、12个月CPSP、6个月CPSNP及PVB相关并发症。
- 采用随机效应模型合并数据,GRADE系统评价证据质量。
临床怎么用
- PVB不应仅以预防CPSP为目的常规用于乳腺癌手术。
- 对于关注神经病理性疼痛风险的患者,PVB可能带来获益,但需结合低质量证据个体化决策。
局限性
- 纳入研究存在局限性,可能导致结果解释受限。
- CPSNP结局证据质量低,需更多高质量研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients frequently report chronic postsurgical pain (CPSP) after breast cancer surgery (BCS). The paravertebral block (PVB) is an effective technique to reduce acute postoperative pain after BCS, but its efficacy in preventing CPSP is unclear. This meta-analysis evaluates the efficacy of PVB in preventing CPSP after BCS. We searched Medline, Embase, CENTRAL, Database of Abstracts of Reviews of Effects, ClinicalTrials.gov, and WHO International Clinical Trials Registry Platform for studies comparing PVB with control for CPSP prevention after BCS, from inception to April 2020. The primary outcome was CPSP at 6 months, and the secondary outcomes were CPSP at 3 and 12 months, chronic postsurgical neuropathic pain (CPSNP) at 6 months, and PVB-related complications. Data were pooled and analyzed with a random-effects model, and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system was used to evaluate the certainty of evidence. A total of 12 studies were included in the study; data for the 6-month time point from 7 studies (2161 patients) were analyzed, and no difference was found between PVB and control in terms of efficacy in preventing CPSP after BCS (risk ratio (RR) 0.82 (95% CI 0.62 to 1.08)), with a moderate quality of evidence according to the GRADE system. Similar results were obtained at 3 and 12 months (RR 0.78 (95% CI 0.57 to 1.06), RR 0.45 (95% CI 0.14 to 1.41), respectively). Data for the 12-month time point from seven studies (2087 patients) were analyzed and showed that PVB protected against CPSNP, with low quality of evidence (RR 0.51 (95% CI 0.31 to 0.85)). In conclusion, CPSP was not found significantly prevented by PVB after BCS despite the limits in the included studies; nevertheless, PVB could prevent CPSNP by impacting the transition from acute to chronic pain.
引用
- Harkouk H, Fletcher D, Martinez V, et al. Paravertebral block for the prevention of chronic postsurgical pain after breast cancer surgery. Reg Anesth Pain Med. 2021. PMID: 33414157. doi:10.1136/rapm-2020-102040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。